- Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
- Chromocell Issues Letter to Stockholders from Chief Executive Officer
- Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
- Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
- Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
- Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
- Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
- Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
More ▼
Key statistics
On Wednesday, Chromocell Therapeutics Corp (CHRO:ASQ) closed at 1.25, 3.31% above its 52-week low of 1.21, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.27 |
---|---|
High | 1.27 |
Low | 1.25 |
Bid | 1.23 |
Offer | 1.30 |
Previous close | 1.27 |
Average volume | 16.67k |
---|---|
Shares outstanding | 5.77m |
Free float | 1.52m |
P/E (TTM) | -- |
Market cap | 7.21m USD |
EPS (TTM) | -1.66 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 22:00 BST.
More ▼